TY - JOUR
T1 - Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO
AU - Rossini, Daniele
AU - Lonardi, Sara
AU - Antoniotti, Carlotta
AU - Santini, Daniele
AU - Tomasello, Gianluca
AU - Ermacora, Paola
AU - Germani, Marco Maria
AU - Bergamo, Francesca
AU - Ricci, Vincenzo
AU - Caponnetto, Salvatore
AU - Moretto, Roberto
AU - Zaniboni, Alberto
AU - Pietrantonio, Filippo
AU - Buonadonna, Angela
AU - Ritorto, Giuliana
AU - Masi, Gianluca
AU - Latiano, Tiziana Pia
AU - Rapisardi, Stefania
AU - Falcone, Alfredo
AU - Cremolini, Chiara
N1 - Funding Information: Funding information The study was supported by GONO and ARCO Foundations (no grant number applicable). Publisher Copyright: © 2020, The Author(s), under exclusive licence to Cancer Research UK. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2021/1/5
Y1 - 2021/1/5
N2 - Background: FOLFOXIRI/bevacizumab (bev) is a first-line regimen of proven activity and efficacy in metastatic colorectal cancer. The upfront exposure to three cytotoxics raises concerns about the efficacy of treatments after progression. Methods: We performed a pooled analysis of treatments after progression to upfront FOLFOXIRI/bev in patients enrolled in two randomised Phase 3 studies (TRIBE and TRIBE2) that compared FOLFOXIRI/bev to doublets (FOLFOX or FOLFIRI)/bev. Response rate, progression-free survival (2nd PFS) and overall survival (2nd OS) during treatments after progression were assessed. The RECIST response in first line and the oxaliplatin and irinotecan-free interval (OIFI) were investigated as potential predictors of benefit from FOLFOXIRI ± bev reintroduction. Results: Longer 2nd PFS was reported in patients receiving FOLFOXIRI ± bev reintroduction compared to doublets ± bev or other treatments (6.1 versus 4.4 and 3.9 months, respectively, P = 0.013), and seems limited to patients achieving a response during first line (6.9 versus 4.2 and 4.7 months, respectively, P = 0.005) and an OIFI ≥ 4 months (7.2 versus 6.5 and 4.6 months, respectively, P = 0.045). Conclusions: First-line FOLFOXIRI/bev does not impair the administration of effective second-line therapies. First-line response and longer OIFI seem associated with improved response and 2nd PFS from FOLFOXIRI ± bev reintroduction, without impacting 2nd OS.
AB - Background: FOLFOXIRI/bevacizumab (bev) is a first-line regimen of proven activity and efficacy in metastatic colorectal cancer. The upfront exposure to three cytotoxics raises concerns about the efficacy of treatments after progression. Methods: We performed a pooled analysis of treatments after progression to upfront FOLFOXIRI/bev in patients enrolled in two randomised Phase 3 studies (TRIBE and TRIBE2) that compared FOLFOXIRI/bev to doublets (FOLFOX or FOLFIRI)/bev. Response rate, progression-free survival (2nd PFS) and overall survival (2nd OS) during treatments after progression were assessed. The RECIST response in first line and the oxaliplatin and irinotecan-free interval (OIFI) were investigated as potential predictors of benefit from FOLFOXIRI ± bev reintroduction. Results: Longer 2nd PFS was reported in patients receiving FOLFOXIRI ± bev reintroduction compared to doublets ± bev or other treatments (6.1 versus 4.4 and 3.9 months, respectively, P = 0.013), and seems limited to patients achieving a response during first line (6.9 versus 4.2 and 4.7 months, respectively, P = 0.005) and an OIFI ≥ 4 months (7.2 versus 6.5 and 4.6 months, respectively, P = 0.045). Conclusions: First-line FOLFOXIRI/bev does not impair the administration of effective second-line therapies. First-line response and longer OIFI seem associated with improved response and 2nd PFS from FOLFOXIRI ± bev reintroduction, without impacting 2nd OS.
U2 - 10.1038/s41416-020-01089-9
DO - 10.1038/s41416-020-01089-9
M3 - Article
VL - 124
SP - 183
EP - 190
JO - Br. J. Cancer
JF - Br. J. Cancer
SN - 0007-0920
IS - 1
ER -